BIOLASE INC (BIOL) Stock Fundamental Analysis

NASDAQ:BIOL • US0909117022

0.129 USD
-0.02 (-13.19%)
At close: Jun 18, 2024
0.109 USD
-0.02 (-15.5%)
After Hours: 6/18/2024, 8:15:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall BIOL gets a fundamental rating of 1 out of 10. We evaluated BIOL against 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of BIOL have multiple concerns. BIOL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BIOL had negative earnings in the past year.
  • BIOL had a negative operating cash flow in the past year.
  • In the past 5 years BIOL always reported negative net income.
  • In the past 5 years BIOL always reported negative operating cash flow.
BIOL Yearly Net Income VS EBIT VS OCF VS FCFBIOL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • BIOL has a Return On Assets of -111.37%. This is amonst the worse of the industry: BIOL underperforms 84.04% of its industry peers.
  • BIOL's Return On Equity of -14222.30% is on the low side compared to the rest of the industry. BIOL is outperformed by 91.49% of its industry peers.
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROIC N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
BIOL Yearly ROA, ROE, ROICBIOL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

  • With a Gross Margin value of 34.26%, BIOL is not doing good in the industry: 69.68% of the companies in the same industry are doing better.
  • BIOL's Gross Margin has been stable in the last couple of years.
  • BIOL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
BIOL Yearly Profit, Operating, Gross MarginsBIOL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • BIOL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BIOL has more shares outstanding
  • The debt/assets ratio for BIOL is higher compared to a year ago.
BIOL Yearly Shares OutstandingBIOL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
BIOL Yearly Total Debt VS Total AssetsBIOL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • BIOL has an Altman-Z score of -13.20. This is a bad value and indicates that BIOL is not financially healthy and even has some risk of bankruptcy.
  • BIOL has a Altman-Z score of -13.20. This is amonst the worse of the industry: BIOL underperforms 83.51% of its industry peers.
  • A Debt/Equity ratio of 41.66 is on the high side and indicates that BIOL has dependencies on debt financing.
  • BIOL has a Debt to Equity ratio of 41.66. This is amonst the worse of the industry: BIOL underperforms 91.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Altman-Z -13.2
ROIC/WACCN/A
WACC12.07%
BIOL Yearly LT Debt VS Equity VS FCFBIOL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • BIOL has a Current Ratio of 1.17. This is a normal value and indicates that BIOL is financially healthy and should not expect problems in meeting its short term obligations.
  • BIOL's Current ratio of 1.17 is on the low side compared to the rest of the industry. BIOL is outperformed by 89.89% of its industry peers.
  • BIOL has a Quick Ratio of 1.17. This is a bad value and indicates that BIOL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.64, BIOL is doing worse than 95.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.64
BIOL Yearly Current Assets VS Current LiabilitesBIOL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.89% over the past year.
  • The Revenue has been growing slightly by 0.13% in the past year.
  • The Revenue has been growing slightly by 1.27% on average over the past years.
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%

3.2 Future

  • Based on estimates for the next years, BIOL will show a very strong growth in Earnings Per Share. The EPS will grow by 41.31% on average per year.
  • The Revenue is expected to grow by 5.36% on average over the next years.
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIOL Yearly Revenue VS EstimatesBIOL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
BIOL Yearly EPS VS EstimatesBIOL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • BIOL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BIOL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOL Price Earnings VS Forward Price EarningsBIOL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOL Per share dataBIOL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BIOL's earnings are expected to grow with 41.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BIOL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOLASE INC

NASDAQ:BIOL (6/18/2024, 8:15:46 PM)

After market: 0.109 -0.02 (-15.5%)

0.129

-0.02 (-13.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13
Earnings (Next)08-08
Inst Owners0%
Inst Owner Change0%
Ins Owners37.15%
Ins Owner Change0%
Market Cap4.31M
Revenue(TTM)48.83M
Net Income(TTM)-38.26M
Analysts80
Price Target1.99 (1442.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.57%
Min EPS beat(2)-107.61%
Max EPS beat(2)32.47%
EPS beat(4)1
Avg EPS beat(4)-58.19%
Min EPS beat(4)-107.61%
Max EPS beat(4)32.47%
EPS beat(8)2
Avg EPS beat(8)-48.85%
EPS beat(12)4
Avg EPS beat(12)-28.48%
EPS beat(16)6
Avg EPS beat(16)-25.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.51%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-8.78%
Min Revenue beat(4)-23.29%
Max Revenue beat(4)-0.64%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)7
Avg Revenue beat(12)1.12%
Revenue beat(16)10
Avg Revenue beat(16)3.28%
PT rev (1m)-82.63%
PT rev (3m)-86.55%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)84.04%
EPS NY rev (1m)-37.5%
EPS NY rev (3m)76.15%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-8.58%
Revenue NY rev (1m)-1.61%
Revenue NY rev (3m)-4.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 16.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.25
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.46
BVpS0.01
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.26%
FCFM N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
F-Score3
Asset Turnover1.42
Health
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.8%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.64
Altman-Z -13.2
F-Score3
WACC12.07%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)202.36%
Cap/Sales(3y)4.06%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.89%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.18%
OCF growth 3YN/A
OCF growth 5YN/A

BIOLASE INC / BIOL FAQ

Can you provide the ChartMill fundamental rating for BIOLASE INC?

ChartMill assigns a fundamental rating of 1 / 10 to BIOL.


What is the valuation status of BIOLASE INC (BIOL) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOLASE INC (BIOL). This can be considered as Overvalued.


What is the profitability of BIOL stock?

BIOLASE INC (BIOL) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIOLASE INC?

The Earnings per Share (EPS) of BIOLASE INC (BIOL) is expected to grow by 98.59% in the next year.